Pharmaceutical Companies– tag –
-
Transcription Factors and DNA Repair Collision: Mutagenesis and Neoantigen Formation as a New Strategy for Cancer Immunotherapy
Introduction: A New Relationship Between Transcription Factors and DNA Repair Recent cancer research has highlighted DNA replication errors and defects in repair mechanisms as central drivers of tumorigenesis. The mismatch repair (MMR) s... -
News Watch: EV × Neurons × Tumor Immunity—Tumor-derived sEVs reprogram nociceptors to drive immunosuppression (with a look at IL-6/IL-6R blockade and potential label expansion) Vol.1
Fresh data in Science Signaling (2025) show that tumor-derived small extracellular vesicles (sEVs) reprogram TRPV1+ nociceptors, boosting IL-6 and Substance P, thereby increasing MDSC infiltration and CD8 T-cell exhaustion—a neuro-immune... -
A New Challenge in Pancreatic Cancer Therapy ― The Promise of “Two Shots on Goal”
Introduction: Why Pancreatic Cancer Is So Difficult to Treat Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, with a dismal 5-year survival rate of about 10%. Three major challenges underlie this poor ... -
Frontiers of Cancer Vaccines for KRAS-mutant Pancreatic Cancer — Comprehensive Summary and Future Outlook
Trilogy Subtitles＋Series Summary Part 1: Biological Background of KRAS-mutant PDAC and Theoretical Basis of Cancer Vaccines Part 2: Clinical Advances in RNA Vaccines and the AMPLIFY-201 Trial Part 3: CAR-T Integration and Next-generatio... -
Frontiers of Cancer Vaccines for KRAS-mutant Pancreatic Cancer — Beyond Immunotherapy Resistance③
Trilogy Subtitles Part 1: Biological Background of KRAS-mutant PDAC and Theoretical Basis of Cancer Vaccines Part 2: Clinical Advances in RNA Vaccines and the AMPLIFY-201 Trial Part 3: CAR-T Integration and Next-generation Vaccine Design... -
Frontiers of Cancer Vaccines for KRAS-mutant Pancreatic Cancer — Beyond Immunotherapy Resistance②
Trilogy Subtitles Part 1: Biological Background of KRAS-mutant PDAC and Theoretical Basis of Cancer Vaccines Part 2: Clinical Advances in RNA Vaccines and the AMPLIFY-201 Trial Part 3: CAR-T Integration and Next-generation Vaccine Design... -
Frontiers of Cancer Vaccines for KRAS-mutant Pancreatic Cancer — Beyond Immunotherapy Resistance①
Trilogy Subtitles Part 1: Biological Background of KRAS-mutant PDAC and Theoretical Basis of Cancer Vaccines Part 2: Clinical Advances in RNA Vaccines and the AMPLIFY-201 Trial Part 3: CAR-T Integration and Next-generation Vaccine Design... -
Summer Beginner Series Grand Summary Part 2｜The Rise of Bispecific Antibodies and the Future of Next-Generation Modalities
This article is the second half of the Morningglorysciences Summer Beginner Series Grand Summary. In Part 1, we reviewed anti-obesity drugs, ADCs, and In vivo CAR-T cell therapy, comparing their strengths and shared challenges. Here in P... -
Can RNA Become a Drug Target? ― Insights from Science and Biotech Frontlines
In recent years, the question of whether RNA can serve as a viable therapeutic target has become one of the most exciting debates in life sciences and drug discovery. Traditionally, drug development has focused on proteins as the primary... -
Latest Science News: Cancer, Obesity, and Aging — New Insights into Immune Recovery through Weight Loss
Recent research highlights that aging and obesity each independently promote cancer progression and can act synergistically to worsen outcomes. However, weight loss appears capable of rejuvenating immune function and suppressing tumor gr... -
Viking Therapeutics’ Obesity Drug Trial Sends Stock Plunging – Market Significance and Biotech Volatility
On August 19, 2025, U.S.-based biotech company Viking Therapeutics announced results from its Phase 2 trial of the oral obesity drug VK2735. While the therapy demonstrated up to 12.2% weight loss over 13 weeks, a high discontinuation rat... -
Summer Beginner Series Grand Summary Part 1｜Anti-Obesity Drugs, ADCs, and In vivo CAR-T — From Beginner to Intermediate Insights
This article is the first half of the Morningglorysciences Summer Beginner Series Grand Summary. We revisit three major therapeutic modalities—anti-obesity drugs, antibody-drug conjugates (ADCs), and In vivo CAR-T cell therapy—highlighti... -
Summer Special Beginner Series Summary｜In vivo CAR-T: Evolution and Future of Cellular Immunotherapy
This article is the comprehensive summary of our Morningglorysciences Summer Beginner Series on “In vivo CAR-T.” Previous articles covered the basics, leading researchers and companies, technical challenges, and global partnerships. Here... -
Summer Special Beginner Series Summary｜Antibody-Drug Conjugates (ADC): Evolution and Future Horizons
This article is the comprehensive summary of our Morningglorysciences Summer Beginner Series on Antibody-Drug Conjugates (ADCs). Throughout the series, we introduced the basics, design principles, historical improvements, and clinical ap... -
Summer Special Beginner Series Summary｜Anti-Obesity Drugs: From GLP-1 to Next-Generation Therapies
This article is a comprehensive summary of our Morningglorysciences Summer Beginner Series on anti-obesity drugs. Throughout the series, we explored the history of obesity treatments, the clinical progress of GLP-1 receptor agonists, and... -
[August 2025 Update] The Frontline of the Obesity Drug Race: Lilly’s Setback, Emerging Biotechs, Big Pharma Strategies, and Chugai’s Moves
Introduction As of August 2025, the obesity drug race is undergoing major shifts. Eli Lilly and Novo Nordisk remain dominant, but biotech challengers and Big Pharma entries are redrawing the competitive map. This article reviews the late... -
Proteins Are “More Stable” Than We Thought: Mega-scale Experiments and Interpretable Models Refresh Design Rules
Even with solved structures, folding thermodynamics (ΔG) has long been hard to see. Recent work closes this gap with mega-scale measurements and a simple scheme—additive energy models with sparse pairwise couplings. This article connects... -
Why Gene & Cell Therapies Stall at the FDA (2024–2025): What Recent CRLs Reveal about CMC, Inspections, and Trial Design
In July 2025, the FDA began publishing past Complete Response Letters (CRLs). Triangulating those releases with company disclosures and primary reporting shows two dominant themes: CMC (quality/manufacturing/testing) & Pre-License In... -
Beginner-Friendly｜Bispecific Antibody Drug Series Vol. 5: Latest Advances and 1-Year Approval Roundup
In this final volume, we summarize the latest developments in bispecific antibody drug R&D by leading biotech and pharma companies, as well as major approvals over the past year in the US and EU. We also highlight key trends and nota... -
Oncology Drug Approval News Flash: FDA Grants Accelerated Approval to Dordaviprone (Modeyso) for H3 K27M-Mutant Diffuse Midline Glioma
On August 6, 2025, the U.S. Food and Drug Administration (FDA) granted accelerated approval to dordaviprone (Modeyso, Jazz Pharmaceuticals), a protease activator, for adult and pediatric patients (≥1 year) with progressive H3 K27M-mutant...
